Eli Lilly's Revenue Soars with Mounjaro and Zepbound, Boosts 2025 Guidance
Originally Published 2 months ago — by investor.lilly.com
Eli Lilly reported a 54% increase in Q3 2025 revenue to $17.6 billion, driven by demand for Mounjaro and Zepbound, and raised its full-year guidance. The company made significant pipeline progress with positive Phase 3 trial results and FDA approval of Inluriyo, while expanding manufacturing capacity with new facilities in Virginia and Texas.